Biotech Values

[urche]

TKM/SRPT
Interesting timing and interesting story with these two companies.

Obviously, this news was favorable to Tekmira, which jumped almost 10% today.

At the same time, Sarepta received news that its Ebola program remains defunded by the Dept of Defense. This ordinarily would have been a big negative for a small company like SRPT. But,of course , all this was massively overshadowed by the results from its muscular dystrophy drug--- the 200% rise of SRPT today gives it a market cap just over $1B. Is anyone besides me feeling this is out of line for a drug that is probably years from approval in a population that is small and will presumably require life-long weekly IV infusions?

Even though I am heartened to see validation for a drug based on antisense technology, I can't help but sense that Sarepta is going to be the victim of short selling pressure and dilution for further studies from here.

Urche